Amibegron

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
Amibegron
(IUPAC) ime
Etil ([(7S)-7-([(2R)-2-(3-hlorofenil)-2-hidroksietil]amino)-5,6,7,8-tetrahidronaftalen-2-il]oksi)acetat
Klinički podaci
Identifikatori
CAS broj 121524-09-2
ATC kod nije dodeljen
PubChem[1][2] 3035442
ChemSpider[3] 108738
UNII PDQ3ME68U3 YesY
KEGG[4] D08851 YesY
ChEMBL[5] CHEMBL545437 YesY
Hemijski podaci
Formula C22H26ClNO4 
Mol. masa 403,898 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status

Amibegron (SR-58,611A) je lek koji je razvio Sanofi. On je selektivni agonist β3 adrenergičkog receptora. On je prvi oralno aktivni β3 agonist koji ima sposobnost ulaska u centralni nervni sistem. Amibegron je antidepresiv i anksiolitik.[6][7]

Sanofi-Aventis je 31. jula 2008. objavio da je razvoj amibegrona prekinut.[8]

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.  edit
  4. Joanne Wixon, Douglas Kell (2000). "Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG". Yeast 17 (1): 48–55. doi:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  5. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  6. Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology. 2008 Feb;33(3):574-87. PMID 17460614
  7. Overstreet DH, Stemmelin J, Griebel G. Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacology, Biochemistry and Behaviour. 2008 Jun;89(4):623-6. DOI:10.1016/j.pbb.2008.02.020 PMID 18358519
  8. Second quarter 2008 results. July 31, 2008, retrieved March 9, 2009.